Back to top
more

Glaukos (GKOS)

(Delayed Data from NYSE)

$110.46 USD

110.46
322,589

+2.84 (2.64%)

Updated May 10, 2024 04:00 PM ET

After-Market: $110.39 -0.07 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Why Is Glaukos (GKOS) Down 0.4% Since Last Earnings Report?

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Glaukos (GKOS) Q3 Earnings Beat Estimates, Revenues Rise Y/Y

Glaukos' (GKOS) third-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.

Glaukos (GKOS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Indrajit Bandyopadhyay headshot

Medical Device Stocks to Watch for Earnings on Nov 1: MCK & More

Medical Device companies' Q3 results are likely to reflect strength in customer demand. Let's see how MCK, QDEL, GKOS and NARI are placed ahead of their earnings release.

Here's Why You Should Retain Glaukos (GKOS) Stock for Now

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Glaukos (GKOS) Q2 Earnings Beat Estimates, Revenues Rise Y/Y

Glaukos' (GKOS) second-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.

Compared to Estimates, Glaukos (GKOS) Q2 Earnings: A Look at Key Metrics

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates

Glaukos (GKOS) delivered earnings and revenue surprises of 3.51% and 7.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

Medical Device Aug 2 Earnings Roster: MCK, FMS & GKOS

Medical Device players are expected to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MCK, FMS and GKOS are likely to have performed this time.

OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of 0% and 1.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Glaukos' (GKOS) New Tie-Up to Address Chronic Eye Disease

Glaukos' (GKOS) new partnership is expected to advance next-generation wearable patient engagement and diagnostic technology, thereby making the detection of eye diseases more efficient.

Glaukos (GKOS) Stock Hits 52-Week High: More Room to Grow?

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Glaukos' (GKOS) Q1 Earnings Beat Estimates, Sales Rise Y/Y

Glaukos' (GKOS) Q1 revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to wider operating loss.

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

Glaukos (GKOS) delivered earnings and revenue surprises of 3.28% and 10.38%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Glaukos' (GKOS) Q4 Earnings Beat Estimates, Sales Decline Y/Y

Glaukos' (GKOS) Q4 revenues beat estimates but fall year over year. Lower revenues, along with higher expenses, hurt margins.

Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates

Glaukos (GKOS) delivered earnings and revenue surprises of 5.36% and 5.19%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

MedTech Stocks' Q4 Earnings on Feb 22: FMS, GKOS & More

MedTech companies' Q4 results are likely to reflect strength in customer demand. Let's see how FMS, GKOS, MMSI and DVA are placed ahead of their earnings releases.

Here's Why You Should Retain Glaukos (GKOS) in Your Portfolio

Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio

Investors continue to be optimistic about Glaukos (GKOS) on the back of continued strength in its flagship iStent.